BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Italiano A, Toulmonde M, Cioffi A, Penel N, Isambert N, Bompas E, Duffaud F, Patrikidou A, Lortal B, Le Cesne A, Blay JY, Maki RG, Schwartz GK, Antonescu CR, Singer S, Coindre JM, Bui B. Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. Ann Oncol. 2012;23:1601-1607. [PMID: 22039081 DOI: 10.1093/annonc/mdr485] [Cited by in Crossref: 72] [Cited by in F6Publishing: 67] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Pedeutour F, Maire G, Pierron A, Thomas DM, Garsed DW, Bianchini L, Duranton-tanneur V, Cortes-maurel A, Italiano A, Squire JA, Coindre J. A newly characterized human well-differentiated liposarcoma cell line contains amplifications of the 12q12-21 and 10p11-14 regions. Virchows Arch 2012;461:67-78. [DOI: 10.1007/s00428-012-1256-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
2 Parkes A, Urquiola E, Bhosale P, Lin H, Watson K, Wang WL, Feig B, Torres K, Roland CL, Conley AP, Zarzour M, Livingston JA, Ratan R, Ludwig J, Araujo DM, Ravi V, Benjamin RS, Patel S, Somaiah N. PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma. Sarcoma 2020;2020:8363986. [PMID: 32565716 DOI: 10.1155/2020/8363986] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Lago S, Nadai M, Ruggiero E, Tassinari M, Marušič M, Tosoni B, Frasson I, Cernilogar FM, Pirota V, Doria F, Plavec J, Schotta G, Richter SN. The MDM2 inducible promoter folds into four-tetrad antiparallel G-quadruplexes targetable to fight malignant liposarcoma. Nucleic Acids Res 2021;49:847-63. [PMID: 33410915 DOI: 10.1093/nar/gkaa1273] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
4 Tseng WW, Malu S, Zhang M, Chen J, Sim GC, Wei W, Ingram D, Somaiah N, Lev DC, Pollock RE, Lizée G, Radvanyi L, Hwu P. Analysis of the intratumoral adaptive immune response in well differentiated and dedifferentiated retroperitoneal liposarcoma. Sarcoma 2015;2015:547460. [PMID: 25705114 DOI: 10.1155/2015/547460] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
5 Thirasastr P, Brahmi M, Dufresne A, Somaiah N, Blay JY. New Drug Approvals for Sarcoma in the Last 5 Years. Surg Oncol Clin N Am 2022;31:361-80. [PMID: 35715139 DOI: 10.1016/j.soc.2022.03.003] [Reference Citation Analysis]
6 Bartlett EK, Curtin CE, Seier K, Qin LX, Hameed M, Yoon SS, Crago AM, Brennan MF, Singer S. Histologic Subtype Defines the Risk and Kinetics of Recurrence and Death for Primary Extremity/Truncal Liposarcoma. Ann Surg 2021;273:1189-96. [PMID: 31283560 DOI: 10.1097/SLA.0000000000003453] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Vay C, Schlünder PM, Dizdar L, Esposito I, Ghadimi MPH, Knoefel WT, Krieg A. Targeting abundant survivin expression in liposarcoma: subtype dependent therapy responses to YM155 treatment. J Cancer Res Clin Oncol 2021. [PMID: 34860309 DOI: 10.1007/s00432-021-03871-5] [Reference Citation Analysis]
8 Toulmonde M, Le Cesne A, Piperno-Neumann S, Penel N, Chevreau C, Duffaud F, Bellera C, Italiano A. Aplidin in patients with advanced dedifferentiated liposarcomas: a French Sarcoma Group Single-Arm Phase II study. Ann Oncol 2015;26:1465-70. [PMID: 26041763 DOI: 10.1093/annonc/mdv195] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
9 Italiano A, Garbay D, Cioffi A, Maki R, Bui B. Advanced pleomorphic liposarcomas: clinical outcome and impact of chemotherapy. Annals of Oncology 2012;23:2205-6. [DOI: 10.1093/annonc/mds219] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
10 Stacchiotti S, Van der Graaf WTA, Sanfilippo RG, Marreaud SI, Van Houdt WJ, Judson IR, Gronchi A, Gelderblom H, Litiere S, Kasper B. First-line chemotherapy in advanced intrabdominal well-differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis. Cancer 2022. [PMID: 35561319 DOI: 10.1002/cncr.34264] [Reference Citation Analysis]
11 Bill KLJ, Seligson ND, Hays JL, Awasthi A, Demoret B, Stets CW, Duggan MC, Bupathi M, Brock GN, Millis SZ, Shakya R, Timmers CD, Wakely PE Jr, Pollock RE, Chen JL. Degree of MDM2 Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma. Oncologist 2019;24:989-96. [PMID: 31019022 DOI: 10.1634/theoncologist.2019-0047] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
12 Roulleaux Dugage M, Nassif EF, Italiano A, Bahleda R. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review. Front Immunol 2021;12:775761. [PMID: 34925348 DOI: 10.3389/fimmu.2021.775761] [Reference Citation Analysis]
13 Constantinidou A, Jones RL. Systemic therapy in retroperitoneal sarcoma management. J Surg Oncol 2018;117:87-92. [DOI: 10.1002/jso.24933] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
14 Saponara M, Stacchiotti S, Gronchi A. Pharmacological therapies for Liposarcoma. Expert Rev Clin Pharmacol. 2017;10:361-377. [PMID: 28135854 DOI: 10.1080/17512433.2017.1289086] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
15 Nishio J, Nakayama S, Nabeshima K, Yamamoto T. Biology and Management of Dedifferentiated Liposarcoma: State of the Art and Perspectives. J Clin Med 2021;10:3230. [PMID: 34362013 DOI: 10.3390/jcm10153230] [Reference Citation Analysis]
16 Harati K, Behr B, Daigeler A, Hirsch T, Jacobsen F, Renner M, Harati A, Wallner C, Lehnhardt M, Becerikli M. Curcumin and Viscum album Extract Decrease Proliferation and Cell Viability of Soft-Tissue Sarcoma Cells: An In Vitro Analysis of Eight Cell Lines Using Real-Time Monitoring and Colorimetric Assays. Nutr Cancer 2017;69:340-51. [PMID: 28045549 DOI: 10.1080/01635581.2017.1263349] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
17 Tseng WW, Somaiah N, Lazar AJ, Lev DC, Pollock RE. Novel systemic therapies in advanced liposarcoma: a review of recent clinical trial results. Cancers (Basel) 2013;5:529-49. [PMID: 24216990 DOI: 10.3390/cancers5020529] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
18 Liverani C, La Manna F, Groenewoud A, Mercatali L, Van Der Pluijm G, Pieri F, Cavaliere D, De Vita A, Spadazzi C, Miserocchi G, Bongiovanni A, Recine F, Riva N, Amadori D, Tasciotti E, Snaar-Jagalska E, Ibrahim T. Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model. Biol Open 2017;6:133-40. [PMID: 27895047 DOI: 10.1242/bio.022483] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
19 Olimpiadi Y, Song S, Hu JS, Matcuk GR, Chopra S, Eisenberg BL, Sener SF, Tseng WW. Contemporary Management of Retroperitoneal Soft Tissue Sarcomas. Curr Oncol Rep 2015;17. [DOI: 10.1007/s11912-015-0462-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
20 Gounder MM, Razak AA, Somaiah N, Chawla S, Martin-Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Riedel RF, Stacchiotti S, Loggers ET, Ganjoo KN, Le Cesne A, Italiano A, Garcia Del Muro X, Burgess M, Piperno-Neumann S, Ryan C, Mulcahy MF, Forscher C, Penel N, Okuno S, Elias A, Hartner L, Philip T, Alcindor T, Kasper B, Reichardt P, Lapeire L, Blay JY, Chevreau C, Valverde Morales CM, Schwartz GK, Chen JL, Deshpande H, Davis EJ, Nicholas G, Gröschel S, Hatcher H, Duffaud F, Herráez AC, Beveridge RD, Badalamenti G, Eriksson M, Meyer C, von Mehren M, Van Tine BA, Götze K, Mazzeo F, Yakobson A, Zick A, Lee A, Gonzalez AE, Napolitano A, Dickson MA, Michel D, Meng C, Li L, Liu J, Ben-Shahar O, Van Domelen DR, Walker CJ, Chang H, Landesman Y, Shah JJ, Shacham S, Kauffman MG, Attia S. Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. J Clin Oncol 2022;:JCO2101829. [PMID: 35394800 DOI: 10.1200/JCO.21.01829] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Kiyuna T, Murakami T, Tome Y, Igarashi K, Kawaguchi K, Miyake K, Miyake M, Li Y, Nelson SD, Dry SM, Singh AS, Russell TA, Singh SR, Kanaya F, Eilber FC, Hoffman RM. Doxorubicin-resistant pleomorphic liposarcoma with PDGFRA gene amplification is targeted and regressed by pazopanib in a patient-derived orthotopic xenograft mouse model. Tissue Cell 2018;53:30-6. [PMID: 30060824 DOI: 10.1016/j.tice.2018.05.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
22 Laroche-Clary A, Chaire V, Algeo MP, Derieppe MA, Loarer FL, Italiano A. Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas. J Hematol Oncol 2017;10:123. [PMID: 28629371 DOI: 10.1186/s13045-017-0482-3] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 10.0] [Reference Citation Analysis]
23 Roy S, Laroche-Clary A, Verbeke S, Derieppe MA, Italiano A. MDM2 Antagonists Induce a Paradoxical Activation of Erk1/2 through a P53-Dependent Mechanism in Dedifferentiated Liposarcomas: Implications for Combinatorial Strategies. Cancers (Basel) 2020;12:E2253. [PMID: 32806555 DOI: 10.3390/cancers12082253] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
24 Chamberlain FE, Wilding C, Jones RL, Huang P. Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma. Expert Opinion on Investigational Drugs 2019;28:505-11. [DOI: 10.1080/13543784.2019.1607291] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
25 Laroche A, Chaire V, Algeo MP, Karanian M, Fourneaux B, Italiano A. MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas. Oncotarget 2017;8:53968-77. [PMID: 28903316 DOI: 10.18632/oncotarget.16345] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
26 Fujimoto R, Sato M, Miyata R, Minakata K, Omasa M, Kubo T, Date H. Successful resection of recurrent mediastinal liposarcoma using preoperative evaluation of organ invasion by four-dimensional computed tomography. Gen Thorac Cardiovasc Surg. 2016;64:488-491. [PMID: 25528654 DOI: 10.1007/s11748-014-0510-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
27 Li ZK, Liu J, Deng YT, Jiang Y. Efficacy and safety of anlotinib in patients with unresectable or metastatic well-differentiated/dedifferentiated liposarcoma: a single-center retrospective study. Anticancer Drugs 2021;32:210-4. [PMID: 33290314 DOI: 10.1097/CAD.0000000000001023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Livingston JA, Bugano D, Barbo A, Lin H, Madewell JE, Wang WL, Lazar AJ, Tseng WW, Roland CL, Feig BW, Pollock R, Conley AP, Benjamin RS, Patel S, Somaiah N. Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard. Sci Rep 2017;7:11836. [PMID: 28928422 DOI: 10.1038/s41598-017-12132-w] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
29 Zuco V, Pasquali S, Tortoreto M, Brich S, Percio S, Dagrada GP, Colombo C, Sanfilippo R, Lauricella C, Gounder M, El Bezawy R, Barisella M, Dei Tos AP, Casali PG, Gronchi A, Stacchiotti S, Zaffaroni N. Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation. J Exp Clin Cancer Res 2021;40:83. [PMID: 33648535 DOI: 10.1186/s13046-021-01886-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Smolle MA, Szkandera J, Andreou D, Palmerini E, Bergovec M, Leithner A. Treatment options in unresectable soft tissue and bone sarcoma of the extremities and pelvis - a systematic literature review. EFORT Open Rev 2020;5:799-814. [PMID: 33312707 DOI: 10.1302/2058-5241.5.200069] [Reference Citation Analysis]
31 In GK, Hu JS, Tseng WW. Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. Ther Adv Med Oncol. 2017;9:533-550. [PMID: 28794805 DOI: 10.1177/1758834017712963] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 8.8] [Reference Citation Analysis]
32 Assi T, Kattan J, Rassy E, Nassereddine H, Farhat F, Honore C, Le Cesne A, Adam J, Mir O. Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review. Critical Reviews in Oncology/Hematology 2020;153:103029. [DOI: 10.1016/j.critrevonc.2020.103029] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
33 Igarashi K, Kawaguchi K, Kiyuna T, Miyake K, Miyaki M, Yamamoto N, Hayashi K, Kimura H, Miwa S, Higuchi T, Singh AS, Chmielowski B, Nelson SD, Russell TA, Eckardt MA, Dry SM, Li Y, Singh SR, Chawla SP, Eilber FC, Tsuchiya H, Hoffman RM. Metabolic targeting with recombinant methioninase combined with palbociclib regresses a doxorubicin-resistant dedifferentiated liposarcoma. Biochem Biophys Res Commun 2018;506:912-7. [PMID: 30392912 DOI: 10.1016/j.bbrc.2018.10.119] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
34 Tseng WW, Barretta F, Conti L, Grignani G, Tolomeo F, Albertsmeier M, Angele MK, Rutkowski P, Skoczylas J, De Paoli A, Navarria F, Raut CP, Fairweather M, Farma JM, Nessim C, Goel N, Grignol VP, Ford SJ, Cardona K, Subhawong T, Tattersall HL, Lee RM, Hu JS, Mehren M, Sanfilippo R, Gronchi A. Defining the role of neoadjuvant systemic therapy in high‐risk retroperitoneal sarcoma: A multi‐institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. Cancer 2021;127:729-38. [DOI: 10.1002/cncr.33323] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
35 Kim YJ, Yu DB, Kim M, Choi YL. Adipogenesis induces growth inhibition of dedifferentiated liposarcoma. Cancer Sci 2019;110:2676-83. [PMID: 31069877 DOI: 10.1111/cas.14036] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
36 Serguienko A, Braadland P, Meza-Zepeda LA, Bjerkehagen B, Myklebost O. Accurate 3-gene-signature for early diagnosis of liposarcoma progression. Clin Sarcoma Res 2020;10:4. [PMID: 32158531 DOI: 10.1186/s13569-020-0126-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Shaker M, Pascarelli KM, Plantinga MJ, Love MA, Lazar AJ, Ingram DR, von Mehren M, Lev D, Kipling D, Broccoli D. Differential expression of cysteine dioxygenase 1 in complex karyotype liposarcomas. Biomark Cancer 2014;6:1-10. [PMID: 24741338 DOI: 10.4137/BIC.S14683] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
38 Penel N, Demetri GD, Blay JY, Cousin S, Maki RG, Chawla SP, Judson I, von Mehren M, Schöffski P, Verweij J, Casali P, Rodenhuis S, Schütte HJ, Cassar A, Gomez J, Nieto A, Zintl P, Pontes MJ, Le Cesne A. Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. Ann Oncol 2013;24:537-42. [PMID: 23117071 DOI: 10.1093/annonc/mds470] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
39 Cai M, Siew CCH, Tay TKY, Tan GHC. Dedifferentiated liposarcoma with a rare presentation of disseminated intraperitoneal sarcomatosis: A case report. Int J Surg Case Rep 2019;60:331-5. [PMID: 31280066 DOI: 10.1016/j.ijscr.2019.06.051] [Reference Citation Analysis]
40 Swallow CJ. Strategic Delay: Histology- and Biology-Driven Decision-Making in Recurrent Retroperitoneal Sarcoma. Ann Surg Oncol 2018;25:2117-9. [DOI: 10.1245/s10434-018-6472-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
41 Bagaria SP, Gabriel E, Mann GN. Multiply recurrent retroperitoneal liposarcoma. J Surg Oncol 2018;117:62-8. [DOI: 10.1002/jso.24929] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
42 Amankwah EK, Conley AP, Reed DR. Epidemiology and therapies for metastatic sarcoma. Clin Epidemiol 2013;5:147-62. [PMID: 23700373 DOI: 10.2147/CLEP.S28390] [Cited by in Crossref: 16] [Cited by in F6Publishing: 55] [Article Influence: 1.8] [Reference Citation Analysis]
43 Harati K, Daigeler A, Hirsch T, Jacobsen F, Behr B, Wallner C, Lehnhardt M, Becerikli M. Tumor-associated fibroblasts promote the proliferation and decrease the doxorubicin sensitivity of liposarcoma cells. Int J Mol Med 2016;37:1535-41. [PMID: 27082154 DOI: 10.3892/ijmm.2016.2556] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
44 Oyebanji TN, Oseni GO, Inuwa IM, Ahmad JI, Garba S, Yusuf L. Refractory bleeding from a giant de-differentiated liposarcoma of the chest wall: An indication for neoadjuvant chemotherapy and palliative resection? - A case report. Int J Surg Case Rep 2018;50:135-9. [PMID: 30121442 DOI: 10.1016/j.ijscr.2018.07.038] [Reference Citation Analysis]
45 Abbas Manji G, Singer S, Koff A, Schwartz GK. Application of Molecular Biology to Individualize Therapy for Patients with Liposarcoma. American Society of Clinical Oncology Educational Book 2015. [DOI: 10.14694/edbook_am.2015.35.213] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
46 Tseng WW, Chopra S, Engleman EG, Pollock RE. Hypothesis: The Intratumoral Immune Response against a Cancer Progenitor Cell Impacts the Development of Well-Differentiated versus Dedifferentiated Disease in Liposarcoma. Front Oncol 2016;6:134. [PMID: 27376027 DOI: 10.3389/fonc.2016.00134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
47 Cornillie J, Wozniak A, Li H, Gebreyohannes YK, Wellens J, Hompes D, Debiec-Rychter M, Sciot R, Schöffski P. Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification. Clin Transl Oncol 2020;22:546-54. [PMID: 31201607 DOI: 10.1007/s12094-019-02158-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
48 Gounder MM, Zer A, Tap WD, Salah S, Dickson MA, Gupta AA, Keohan ML, Loong HH, D'Angelo SP, Baker S, Condy M, Nyquist-Schultz K, Tanner L, Erinjeri JP, Jasmine FH, Friedlander S, Carlson R, Unger TJ, Saint-Martin JR, Rashal T, Ellis J, Kauffman M, Shacham S, Schwartz GK, Abdul Razak AR. Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma. J Clin Oncol 2016;34:3166-74. [PMID: 27458288 DOI: 10.1200/JCO.2016.67.6346] [Cited by in Crossref: 88] [Cited by in F6Publishing: 53] [Article Influence: 14.7] [Reference Citation Analysis]
49 Ishii T, Kohashi K, Iura K, Maekawa A, Bekki H, Yamada Y, Yamamoto H, Nabeshima K, Kawashima H, Iwamoto Y, Oda Y. Activation of the Akt-mTOR and MAPK pathways in dedifferentiated liposarcomas. Tumour Biol 2016;37:4767-76. [PMID: 26518767 DOI: 10.1007/s13277-015-4232-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
50 Blay J, Sleijfer S, Schöffski P, Kawai A, Brodowicz T, Demetri GD, Maki RG. International expert opinion on patient-tailored management of soft tissue sarcomas. European Journal of Cancer 2014;50:679-89. [DOI: 10.1016/j.ejca.2013.11.011] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
51 Evola G, Schillaci R, Reina M, Caruso G, D'angelo M, Reina GA. Giant retroperitoneal well-differentiated liposarcoma presenting in emergency with intestinal occlusion: Case report and review of the literature. International Journal of Surgery Case Reports 2022;95:107152. [DOI: 10.1016/j.ijscr.2022.107152] [Reference Citation Analysis]
52 Zheng QG, Sun ZH, Chen JJ, Li JC, Huang XJ. Paratesticular liposarcoma: Two case reports. World J Clin Cases 2021; 9(2): 457-462 [PMID: 33521115 DOI: 10.12998/wjcc.v9.i2.457] [Reference Citation Analysis]
53 Kollár A, Benson C. Current management options for liposarcoma and challenges for the future. Expert Review of Anticancer Therapy 2014;14:297-306. [DOI: 10.1586/14737140.2014.869173] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
54 Henze J, Bauer S. Liposarcomas. Hematology/Oncology Clinics of North America 2013;27:939-55. [DOI: 10.1016/j.hoc.2013.07.010] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
55 Manji GA, Schwartz GK. Managing Liposarcomas: Cutting Through the Fat. JOP 2016;12:221-7. [DOI: 10.1200/jop.2015.009860] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
56 Shurell E, Vergara-Lluri ME, Li Y, Crompton JG, Singh A, Bernthal N, Wu H, Eilber FC, Dry SM. Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma. Oncotarget 2016;7:72860-7. [PMID: 27655679 DOI: 10.18632/oncotarget.12096] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
57 Avancès C, Rigaud J, Camparo P, Durand X, Sèbe P, Fléchon A, Murez T, Coloby P, Soulié M; Les membres du CCAFU. [CCAFU's contribution to the French National Cancer Institute's reference frame: Retroperitoneal sarcomas]. Prog Urol 2013;23 Suppl 2:S161-6. [PMID: 24485290 DOI: 10.1016/S1166-7087(13)70053-8] [Reference Citation Analysis]
58 De Vita A, Mercatali L, Recine F, Pieri F, Riva N, Bongiovanni A, Liverani C, Spadazzi C, Miserocchi G, Amadori D, Ibrahim T. Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas. Onco Targets Ther 2016;9:6233-46. [PMID: 27785071 DOI: 10.2147/OTT.S112580] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
59 Gahvari Z, Parkes A. Dedifferentiated Liposarcoma: Systemic Therapy Options. Curr Treat Options Oncol 2020;21:15. [PMID: 32026050 DOI: 10.1007/s11864-020-0705-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
60 Thoenen E, Curl A, Iwakuma T. TP53 in bone and soft tissue sarcomas. Pharmacol Ther 2019;202:149-64. [PMID: 31276706 DOI: 10.1016/j.pharmthera.2019.06.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
61 Alessandrini I, Percio S, Naghshineh E, Zuco V, Stacchiotti S, Gronchi A, Pasquali S, Zaffaroni N, Folini M. Telomere as a Therapeutic Target in Dedifferentiated Liposarcoma. Cancers (Basel) 2022;14:2624. [PMID: 35681604 DOI: 10.3390/cancers14112624] [Reference Citation Analysis]
62 McGovern Y, Zhou CD, Jones RL. Systemic Therapy in Metastatic or Unresectable Well-Differentiated/Dedifferentiated Liposarcoma. Front Oncol 2017;7:292. [PMID: 29250486 DOI: 10.3389/fonc.2017.00292] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
63 Wang D, Wu J, Yu J, Zhang H, Liu H. Solitary pancreatic metastasis of extremity myxoid liposarcoma: a case report and literature review. BMC Cancer 2018;18:1121. [PMID: 30445938 DOI: 10.1186/s12885-018-5059-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
64 Harati K, Behr B, Wallner C, Daigeler A, Hirsch T, Jacobsen F, Renner M, Harati A, Lehnhardt M, Becerikli M. Anti‑proliferative activity of epigallocatechin‑3‑gallate and silibinin on soft tissue sarcoma cells. Mol Med Rep 2017;15:103-10. [PMID: 27909727 DOI: 10.3892/mmr.2016.5969] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
65 Toulmonde M, Bonvalot S, Ray-Coquard I, Stoeckle E, Riou O, Isambert N, Bompas E, Penel N, Delcambre-Lair C, Saada E, Lecesne A, Le Péchoux C, Blay JY, Piperno-Neumann S, Chevreau C, Bay JO, Brouste V, Terrier P, Ranchère-Vince D, Neuville A, Italiano A; French Sarcoma Group. Retroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. Ann Oncol 2014;25:730-4. [PMID: 24496921 DOI: 10.1093/annonc/mdt576] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
66 Lee EM, Kim DH, Kim DY, Seol YM, Choi YJ, Kim H. Efficacy of adjuvant radiotherapy in non-extremity soft tissue sarcoma with moderate chemosensitivity. Radiat Oncol J 2018;36:325-31. [PMID: 30630271 DOI: 10.3857/roj.2018.00262] [Reference Citation Analysis]
67 Chamberlain F, Benson C, Thway K, Huang P, Jones RL, Gennatas S. Pharmacotherapy for liposarcoma: current and emerging synthetic treatments. Future Oncol 2021;17:2659-70. [PMID: 33880964 DOI: 10.2217/fon-2020-1092] [Reference Citation Analysis]
68 Sánchez-hidalgo JM, Rufián-peña S, Durán-martínez M, Arjona-sánchez Á, Salcedo-leal I, Lopez-cillero P, Briceño-delgado J. Factores de riesgo implicados en la recurrencia precoz del liposarcoma retroperitoneal. Cirugía Española 2018;96:568-76. [DOI: 10.1016/j.ciresp.2018.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
69 Kapodistrias N, Mavridis K, Batistatou A, Gogou P, Karavasilis V, Sainis I, Briasoulis E, Scorilas A. Assessing the clinical value of microRNAs in formalin-fixed paraffin-embedded liposarcoma tissues: Overexpressed miR-155 is an indicator of poor prognosis. Oncotarget. 2017;8:6896-6913. [PMID: 28036291 DOI: 10.18632/oncotarget.14320] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
70 Somaiah N, Beird HC, Barbo A, Song J, Mills Shaw KR, Wang WL, Eterovic K, Chen K, Lazar A, Conley AP, Ravi V, Hwu P, Futreal A, Simon G, Meric-Bernstam F, Hong D. Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. Oncotarget 2018;9:19891-9. [PMID: 29731991 DOI: 10.18632/oncotarget.24924] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
71 Liu J, Song Z, Liu R, Liu M, Ren D, Zhou Q, Chen J. [Relapsed Pleomorphic Liposarcoma with Mediastinal Metastasis: A Case Report 
and Review of the Literature]. Zhongguo Fei Ai Za Zhi 2017;20:361-5. [PMID: 28532545 DOI: 10.3779/j.issn.1009-3419.2017.05.10] [Reference Citation Analysis]
72 Vos M, Grünhagen DJ, Koseła-Paterczyk H, Rutkowski P, Sleijfer S, Verhoef C. Natural history of well-differentiated liposarcoma of the extremity compared to patients treated with surgery. Surg Oncol 2019;29:84-9. [PMID: 31196499 DOI: 10.1016/j.suronc.2019.04.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
73 Thirasastr P, Somaiah N. Overview of systemic therapy options in liposarcoma, with a focus on the activity of selinexor, a selective inhibitor of nuclear export in dedifferentiated liposarcoma. Ther Adv Med Oncol 2022;14:175883592210810. [DOI: 10.1177/17588359221081073] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 de Arruda JAA, Arantes DAC, Schuch LF, Abreu LG, de Andrade BAB, Romañach MJ, Mesquita RA, Watanabe S, de Oliveira JC, Mendonça EF. Inflammatory Variant of Atypical Lipomatous Tumor/Well-Differentiated Liposarcoma of the Buccal Mucosa: An Overview and Case Report with a 10-Year Follow-Up. Head Neck Pathol 2021;15:1031-40. [PMID: 33091145 DOI: 10.1007/s12105-020-01242-z] [Reference Citation Analysis]
75 Volkov AY, Nered SN, Kozlov NA, Stilidi IS, Archery PP, Antonova EY, Privezentsev SA. [Active surgical approach for retroperitoneal liposarcoma]. Khirurgiia (Mosk) 2021;:5-11. [PMID: 34786910 DOI: 10.17116/hirurgia20211115] [Reference Citation Analysis]
76 Fabbroni C, Fucà G, Ligorio F, Fumagalli E, Barisella M, Collini P, Morosi C, Gronchi A, Dei Tos AP, Casali PG, Sanfilippo R. Impact of Pathological Stratification on the Clinical Outcomes of Advanced Well-Differentiated/Dedifferentiated Liposarcoma Treated with Trabectedin. Cancers (Basel) 2021;13:1453. [PMID: 33810165 DOI: 10.3390/cancers13061453] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
77 Mansfield SA, Pollock RE, Grignol VP. Surgery for Abdominal Well-Differentiated Liposarcoma. Curr Treat Options Oncol 2018;19:1. [PMID: 29335908 DOI: 10.1007/s11864-018-0520-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
78 Sanfilippo R, Bertulli R, Marrari A, Fumagalli E, Pilotti S, Morosi C, Messina A, Dei Tos AP, Gronchi A, Casali PG. High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma. Clin Sarcoma Res 2014;4:16. [PMID: 25628856 DOI: 10.1186/2045-3329-4-16] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
79 Bhosale P, Wang J, Varma D, Jensen C, Patnana M, Wei W, Chauhan A, Feig B, Patel S, Somaiah N, Sagebiel T. Can Abdominal Computed Tomography Imaging Help Accurately Identify a Dedifferentiated Component in a Well-Differentiated Liposarcoma? J Comput Assist Tomogr 2016;40:872-9. [PMID: 27454788 DOI: 10.1097/RCT.0000000000000462] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]